Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution
Oncology · 2024
DOI: 10.1159/000541891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Margherita Rimini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute University San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combinationʼs real-world efficacy and tolerability, we conducted a retrospective analysis of its first-line treatment outcomes.
Methods
We included patients with unresectable, locally advanced, or metastatic BTC treated with cisplatin, gemcitabine, plus durvalumab. The primary endpoint was overall survival (OS).
Results
Thirty-three patients were enrolled. Median OS was NR and median progression free survival (PFS) was 7.6 months, after a median follow-up of 13.5 months. The investigator-assessed overall response rate was 34.5%, with stable disease in 53.0% of patients. High baseline CEA levels were associated with poor survival. Any grade adverse events (AEs) occurred in 97% of patients. Immune-related AEs (irAEs) occurred in 16% (grade >2: 6%). Presence of TP53 mutation was related to a worse OS; conversely the presence of ARID1A genomic alteration was related to a better PFS. A tendence toward a better OS was found for BRCAness patients which did not reach the statistical significance. On the other hand, BRCAness patients showed significantly higher PFS compared to no BRCAness patients.
Conclusion
This real-world analysis largely confirmed the TOPAZ-1 findings, supporting gemcitabine, cisplatin, and durvalumab as a first-line standard of care for patients with advanced BTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vita-Salute University San Raffaele, Milan, Italy.
- IRCCS San Raffaele Hospital, Oncology Department, Milan, Italy.
- Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Oncology Department, University Hospital of Cagliari, Cagliari, Italy.
Zitieren
APA
Rimini, M., Foti, S., Camera, S., Rossari, F., Vitiello, F., Lo Prinzi, F., Aldrighetti, L., De Cobelli, F., Pedica, F., Arcidiacono, P. G., Persano, M., Cascinu, S., & Casadei-Gardini, A. (2024). Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution. Oncology. https://doi.org/10.1159/000541891
Vancouver
Rimini M, Foti S, Camera S, Rossari F, Vitiello F, Lo Prinzi F, et al. Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution. Oncology. 2024. doi:10.1159/000541891
BibTeX
@article{Rimini2024,
author = {Rimini, Margherita and Foti, Silvia and Camera, Silvia and Rossari, Federico and Vitiello, Francesco and Lo Prinzi, Federica and Aldrighetti, Luca and De Cobelli, Francesco and Pedica, Federica and Arcidiacono, Paolo Giorgio and Persano, Mara and Cascinu, Stefano and Casadei-Gardini, Andrea},
title = {Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution},
journal = {Oncology},
year = {2024},
doi = {10.1159/000541891}
}
EUVIMED